

July 3, 2023  
Web Announcement 3109

## Drug Use Review (DUR) Board Approves Changes Effective July 3, 2023.

The Nevada Medicaid Drug Use Review (DUR) Board met on April 20, 2023 and voted to adopt the following changes effective July 3, 2023:

Drug Class/Program	Changes
Verkazia® (cyclosporine)	Addition of new clinical criteria
Anticonvulsants	Addition of new clinical criteria to Ztalmy® (ganaxolone)  Updates to existing clinical criteria to Epidiolex® (cannabidiol)
Alzheimer's disease	Addition of new clinical criteria to Leqembi® (lecanemab-irmb)

Prior Authorization forms may be found on the below webpages:  
<https://nevadamedicaid.magellanrx.com/provider/forms> (pharmacy/point-of-sale)